La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Inhibrx Biosciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Inhibrx Biosciences..

Inhibrx Biosciences (NASDAQ:INBX) Azioni, Catena delle Opzioni

INHIBRX BIOSCIENCES INC

Inhibrx

Inhibrx Biosciences

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Inhibrx Biosciences Inc

Inhibrx Inc COM

News

General

BLNK

Blink Charging Receives Letter From Nasdaq Regarding Late Filing Of Form 10-K

Citigroup analyst Scott Gruber maintains Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) with a Buy and lowers the price target from $33 to $32.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Helmerich & Payne, Lowers Price Target to $32

Unifirst Declares Regular Cash Dividends; New $100M Share Repurchase Authorization

Citigroup analyst Scott Gruber maintains Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) with a Buy and lowers the price target from $54 to $53.

Citigroup Maintains Buy on Baker Hughes, Lowers Price Target to $53

Citigroup analyst Patrick Cunningham maintains Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) with a Buy and lowers the price target from $423 to $375.

Citigroup Maintains Buy on Sherwin-Williams, Lowers Price Target to $375

Citigroup analyst Patrick Cunningham maintains PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) with a Buy and lowers the price target from $135 to $113.

Citigroup Maintains Buy on PPG Indus, Lowers Price Target to $113

Citigroup analyst Patrick Cunningham maintains Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) with a Buy and lowers the price target from $99 to $84.

Citigroup Maintains Buy on Intl Flavors & Fragrances, Lowers Price Target to $84

NSYS

Nortech Systems Reveals New Patent For Non-Magnetic Expanded Beam Fiber Optic Cable Technology.

Citigroup analyst Patrick Cunningham maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Buy and lowers the price target from $305 to $275.

Citigroup Maintains Buy on Ecolab, Lowers Price Target to $275

Peabody Energy Announces It Is Reviewing All Options Regarding The Acquisition Of Steelmaking Coal Assets From Anglo American

Citigroup analyst Patrick Cunningham maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Buy and lowers the price target from $95 to $74.

Citigroup Maintains Buy on DuPont de Nemours, Lowers Price Target to $74

Citigroup analyst Patrick Cunningham maintains Axalta Coating Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) with a Neutral and lowers the price target from $42 to $32.

AXTA

Citigroup Maintains Neutral on Axalta Coating Systems, Lowers Price Target to $32

As Jazz Pharmaceuticals plc (the "Company") has previously disclosed, a number of complaints, including, from June 2020 to September 2020, several complaints styled as class actions and, from March 2021 to May 2022, several additional complaints, were filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the Company's actions leading up to, and entering into, patent litigation settlement agreements with generic drug manufacturers who had filed abbreviated new drug applications ("ANDAs" and such filers, "ANDA filers"), violate U.S. state and federal antitrust, consumer protection and unfair competition laws. This group of cases was consolidated for multidistrict litigation ("MDL") proceedings before the U.S. District Court for the Northern District of California (the "Court") in December 2020.
On April 7, 2025, Jazz Pharmaceuticals Ireland Limited, a wholly-owned subsidiary of the Company, entered into a preliminary class settlement agreement (the "preliminary class settlement agreement") with the class of indirect Xyrem purchasers to settle all claims of participating class members against the Company with respect to the Company's actions leading up to, and entering into, patent litigation settlement agreements with the ANDA filers.
Pursuant to the preliminary class settlement agreement, which was entered into with counsel representing the class representatives, the Company has agreed to pay a total of $145&nbsp;million in a lump sum. The Company plans to use cash on hand to fund the preliminary class settlement agreement's obligations. The Company expects to record a pre-tax charge of approximately $145&nbsp;million associated with this preliminary class settlement agreement in the first quarter of 2025.

Legal

JAZZ

Jazz Pharmaceuticals Enters Preliminary $145M Class Settlement Agreement To Resolve Antitrust And Consumer Protection Claims Related To Patent Litigation Settlements For Xyrem, Expected To Record Pre-Tax Charge In Q1 2025

Nio Files 2024 Annual Report On Form 20-F For FY24 With The SEC

Citigroup analyst Christopher Allen maintains Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) with a Neutral and lowers the price target from $55 to $39.

Citigroup Maintains Neutral on Carlyle Group, Lowers Price Target to $39

Citigroup analyst Chris Allen maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Buy and lowers the price target from $177 to $132.

Citigroup Maintains Buy on KKR, Lowers Price Target to $132

Citigroup analyst Chris Allen maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Neutral and lowers the price target from $190 to $137.

Citigroup Maintains Neutral on Blackstone, Lowers Price Target to $137

Citigroup analyst Chris Allen maintains Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Buy and lowers the price target from $191 to $138.

Citigroup Maintains Buy on Apollo Global Management, Lowers Price Target to $138

<h3>Gainers</h3>
<ul>
<li>Aureus Greenway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) stock increased by 39.0% to $1.14 during Tuesday's after-market session. The company's market cap stands at $15.8 million. </li>
<li>Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) stock increased by 20.01% to $0.45. The company's market cap stands at $19.2 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) shares rose 11.11% to $2.0. The market value of their outstanding shares is at $9.4 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) stock increased by 9.53% to $0.17. The market value of their outstanding shares is at $68.1 million. </li>
<li>Rent the Runway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) stock increased by 9.03% to $4.79. The company's market cap stands at $18.5 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares moved upwards by 6.27% to $1.02. The company's market cap stands at $19.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MKDWell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) stock decreased by 10.1% to $0.36 during Tuesday's after-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>SAG Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAG#NASDAQ">SAG</a>) stock fell 9.31% to $0.68. The company's market cap stands at $6.7 million. </li>
<li>Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) stock declined by 8.34% to $0.13. The market value of their outstanding shares is at $7.8 million. </li>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) stock decreased by 6.23% to $2.41. The market value of their outstanding shares is at $5.7 million. </li>
<li>Nxu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) shares fell 5.1% to $2.42. The company's market cap stands at $5.3 million. </li>
<li>Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) stock declined by 4.77% to $1.2. The company's market cap stands at $64.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

DXLG

LVLU

MKDW

QVCGA

RENT

RIME

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares rose 129.5% to $6.61 during Tuesday's after-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares moved upwards by 60.8% to $1.28. The market value of their outstanding shares is at $2.6 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares increased by 34.26% to $1.09. The company's market cap stands at $1.8 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) shares moved upwards by 13.98% to $2.2. The market value of their outstanding shares is at $10.8 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock moved upwards by 12.12% to $0.37. The company's market cap stands at $7.6 million. </li>
<li>Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) shares moved upwards by 10.88% to $2.63. The market value of their outstanding shares is at $84.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock declined by 55.6% to $0.24 during Tuesday's after-market session. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares declined by 14.31% to $6.11. The market value of their outstanding shares is at $4.6 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares fell 12.69% to $0.24. The company's market cap stands at $1.8 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock declined by 12.26% to $0.62. The market value of their outstanding shares is at $2.4 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock declined by 11.39% to $3.27. The company's market cap stands at $2.9 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) stock decreased by 8.36% to $0.82. The company's market cap stands at $19.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABVC

AEMD

ANIX

ATNF

NAOV

NAYA

PTIX

REVB

SLRX

VERO

VINC

WORX

12 Health Care Stocks Moving In Tuesday's After-Market Session

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWN, INBX, AVRO

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

Earnings

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

AVRO

INBX

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Inhibrx Biosciences

Inhibrx Biosciences (INBX) Opzioni

Inhibrx Biosciences (NASDAQ:INBX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO